Cocrystal Pharma Reports Positive Phase 1 Study Results

Cocrystal Pharma ( (COCP) ) has issued an announcement.

On August 5, 2025, Cocrystal Pharma announced the presentation of positive safety and tolerability data from a Phase 1 study of its oral pan-viral inhibitor CDI-988 at the Military Health System Research Symposium. The study showed that CDI-988 was well tolerated across all doses, supporting its continued development as a potential treatment for norovirus, a virus with no approved treatments or vaccines. The company plans to initiate a Phase 1b study later this year, highlighting CDI-988’s potential as a prophylactic and therapeutic solution for norovirus outbreaks, particularly in military settings where the virus poses significant risks.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.

To see Spark’s full report on COCP stock, click here.

More about Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics. The company targets the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses using unique structure-based technologies.

Average Trading Volume: 58,590

Technical Sentiment Signal: Sell

Current Market Cap: $18.82M

Learn more about COCP stock on TipRanks’ Stock Analysis page.